Key facts
- What it is: Follistatin-344 is an isoform of follistatin, a human glycoprotein that binds activins and can inhibit myostatin-related signaling.
- Evidence: Animal and observational safety evidence; no validated performance use.
- Status: Unapproved experimental biologic.
- Main caution: Potential concerns include off-target activin effects, reproductive and vascular consequences, immune reactions, and ocular events.
- Sources: 5 PubMed-indexed papers linked below.
What is Follistatin-344?
Follistatin-344 is an isoform of follistatin, a human glycoprotein that binds activins and can inhibit myostatin-related signaling. The biology makes it attractive to muscle-growth marketing. Black-market products labeled FST-344 are not approved medicines and may not match research-grade material.
The first SEO trap with peptide content is treating every compound as if it belongs to the same category. It does not. Some peptides are approved prescription medicines supported by randomized trials; others are endogenous signaling molecules being studied in cells; others are unapproved chemicals sold with no regulated manufacturing chain. For Follistatin-344, the evidence and regulatory category above determine what conclusions are reasonable.
This guide does not provide a dose, cycle, protocol, source, or personal recommendation. It translates published research so readers can distinguish a measured result from a marketing claim and bring better questions to a licensed clinician.
How does Follistatin-344 work?
By binding members of the TGF-beta superfamily, follistatin can alter signals that restrain muscle growth and regulate reproduction, metabolism, and tissue repair. The pathway is broad rather than muscle-specific, which makes systemic manipulation biologically complex.
Mechanism is not the same as clinical benefit. A compound can activate a receptor, change a biomarker, or improve an animal model without improving how people feel, function, or survive. The strongest medical claims require controlled human outcomes, not a plausible pathway alone.
What does the research on Follistatin-344 show?
Transgenic animal studies demonstrate increased muscle mass when follistatin-344 expression is driven experimentally. Anti-doping laboratories have identified products sold on the black market, and a small case series reported central serous chorioretinopathy after high-dose use. Controlled human efficacy trials for recreational injection are absent.
These papers were selected to show the shape of the evidence: foundational biology, clinical trials where they exist, safety signals, and reviews that place single studies in context. A citation does not mean PepMate endorses a treatment; it lets readers inspect the original record.
How strong is the evidence?
Evidence assessment: Animal and observational safety evidence; no validated performance use. Gene-therapy experiments, transgenic animals, and unverified vials are not interchangeable forms of evidence. The absence of controlled trials leaves dose-response, durability, and long-term harms unresolved.
Evidence strength depends on study design, directness, replication, sample size, and whether researchers measured a meaningful outcome. Animal evidence can justify a human trial, but it cannot establish a human treatment. Observational human data can identify associations, but it cannot reliably prove cause and effect.
Is Follistatin-344 approved or available?
Unapproved experimental biologic. Approval is tied to a specific product, indication, population, formulation, and regulator. “Research use only,” clinic availability, compounding, or a listing on a peptide website is not the same as approval. Availability can change, so current regulator labeling and professional guidance take priority over any static article.
Follistatin-344 safety, risks, and evidence gaps
Potential concerns include off-target activin effects, reproductive and vascular consequences, immune reactions, and ocular events. Product identity and sterility cannot be assumed. Follistatin-related manipulation is prohibited in sport.
Gene-therapy experiments, transgenic animals, and unverified vials are not interchangeable forms of evidence. The absence of controlled trials leaves dose-response, durability, and long-term harms unresolved.
Unapproved online peptides add risks that a paper about a verified laboratory compound cannot measure: mislabeling, contamination, sterility failure, degradation, and a concentration different from the label. Even an endogenous or short peptide can cause harm when the route, exposure, or manufacturing quality changes.
Frequently asked questions
What is Follistatin-344?
Follistatin-344 is an isoform of follistatin, a human glycoprotein that binds activins and can inhibit myostatin-related signaling. The biology makes it attractive to muscle-growth marketing. Black-market products labeled FST-344 are not approved medicines and may not match research-grade material.
How does Follistatin-344 work?
By binding members of the TGF-beta superfamily, follistatin can alter signals that restrain muscle growth and regulate reproduction, metabolism, and tissue repair. The pathway is broad rather than muscle-specific, which makes systemic manipulation biologically complex.
Is Follistatin-344 FDA-approved?
Unapproved experimental biologic. Approval is indication-specific and can differ by country; check current regulator labeling rather than relying on peptide-shop descriptions.
What does PubMed research on Follistatin-344 show?
Transgenic animal studies demonstrate increased muscle mass when follistatin-344 expression is driven experimentally. Anti-doping laboratories have identified products sold on the black market, and a small case series reported central serous chorioretinopathy after high-dose use. Controlled human efficacy trials for recreational injection are absent.
What are the main risks of Follistatin-344?
Potential concerns include off-target activin effects, reproductive and vascular consequences, immune reactions, and ocular events. Product identity and sterility cannot be assumed. Follistatin-related manipulation is prohibited in sport.
PubMed sources
Every medical claim in this guide is anchored to peer-reviewed or scholarly literature indexed on PubMed. Open the abstracts below to review the study design, population, and limitations.
- The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs. — PubMed 27787698 (2017)
- Detection of black market follistatin 344. — PubMed 31758732 (2019)
- Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. — PubMed 32671599 (2020)
- Detection of black market follistatin 344. — PubMed 33460286 (2020)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — PubMed 41966639 (2026)
Source selection and update method: PepMate Research Editorial Policy. Last updated 22 July 2026.